Aarkstore.com announces 10% Discount on this report till 6th April 2012
Licensing Strategies of Large Pharmaceutical Companies Weak R&D Pipelines and the Patent Cliff Stimulate InLicensing Activity http://www.aarkstore.com/reports/Licensing-Strategies-of-Large-PharmaceuticalCompanies-Weak-R-D-Pipelines-and-the-Patent-Cliff-Stimulate-In-LicensingActivity-155019.html
RSS Link Discount offer till 30th April 2012
Summary Company Research has released its latest research, “Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate InLicensing Activity” which provides insights into the licensing agreements of large pharmaceutical companies. The report provides an in-depth analysis of the major licensing agreement trends in the pharmaceutical industry along with product and technology licensing trends. In addition, the report also analyzes the top 20 pharmaceutical companies with respect to the licensing agreement activities. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by Company Research’s team of industry experts. Scope The scope of this report includes - Major market trends that are expected to shape the licensing and deal making landscape
in pharmaceutical industry - Trends in deals for product licensing and technology licensing agreements. - Extensive research and analysis of the licensing activity of large pharmaceutical companies. Table of Contents : 1.1 List of Tables 7 1.2 List of Figures 8 2 Licensing Strategies In Large Pharmaceutical Companies – Introduction 13 2.1 Licensing Agreement – An Authorization 13 2.2 GBI Research Report Guidance 15 3 Trends in In-licensing and Out-licensing Agreements 16 3.1 In-Licensing Compensates For Declining Internal R&D 16 3.2 Licensing Key To Combat Patent Cliff 16 3.3 Spiraling Cost of Licensing Deals 16 3.3.1 Competition to Restock Pipelines 16 3.3.2 Biotechs Push Products through Further Stages of Development 16 4 Product Licensing 18 4.1 Licensing Offsets Deficiencies in Internal Pipelines and Portfolios 18 4.2 Oncology Therapy Area Spearheads Licensing Agreements in Big Pharma Companies 18 4.3 Licensing Deals in Asia-Pacific on the Rise 19 5 Technology Licensing Deals 20 5.1 Importance of Technology In-Licensing 20 5.2 Technology Licensing With Universities 20 6 Major Licensing Deals of Big Pharma Companies – 2010 21 6.1 High Value Deals of Big Pharma Players – 2010 21 6.1.1 GlaxoSmithKline Enters Into Licensing Agreement with Isis Pharmaceuticals 21 6.1.2 Sanofi-Aventis enters Into Licensing Agreement with Avila Therapeutics 22 6.1.3 Boehringer Ingelheim Enters into Licensing Agreement With f-star Biotechnologische 22 6.1.4 Merck Amends Its Collaboration Agreement with Ariad Pharmaceuticals 23 6.1.5 AstraZeneca Enters Into Licensing Agreement with Rigel Pharmaceuticals 23 For more related Reports Plz follow The link:
Floating Production Storage and Offloading (FPSO) and Floating Storage and Offloading (FSO) Industry to 2016 - Rise of Deepwater Hydrocarbon Production Leading to Industry Growth Spinal Surgery Devices Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 - Motion Preserving Spinal Non-Fusion Procedures to Drive Long Term Growth Emerging Countries Cardiovascular Devices Market to 2017 - Increasing Incidence of Cardiovascular Diseases and Lifestyle Disorders to Drive the Market Veterinary Vaccines Market to 2017 - Europe to Strengthen Its Position as the Single Largest Market for Animal Vaccines Due To Highly Organized Livestock Farms
Category Reports: Automobile, Aerospace & Aviation, Banking, Consumer Goods, Construction, Chemicals, Defense, Diabetes, Disease, Drinks, Energy, Electronics, Financial , Food & Drinks, Glass, Healthcare, Insurance, Information technology
For More details Plz do contact : Aarkstore Enterprise Marketing Team ( janavi ) Phone:08149852585 Email: enquiry@aarkstore.com